The Clinical Times
The Front Page of Medicine

Global Health · page 11

UK, EU & international health agencies

UKHSA (UK) · Jul 9, 2026

Accredited official statistics: Quarterly Epidemiological Commentary: mandatory MRSA, MSSA and Gram-negative bacteraemia and Clostridioides difficile infection, data up to January to March 2027

Epidemiological analyses of mandatory surveillance data on healthcare associated infections (HCAI); MRSA, MSSA and Gram-negative bacteraemia (Escherichia coli (E. coli), Pseudomonas aeruginosa ( P. aeruginoa), Klebsiella species (Klebsiella spp.)), and Clostridioides difficile (C. difficile) infection.

UKHSA (UK) · Jul 9, 2026

Accredited official statistics: Quarterly Epidemiological Commentary: mandatory MRSA, MSSA and Gram-negative bacteraemia and Clostridioides difficile infection, data up to October to December 2026

Epidemiological analyses of mandatory surveillance data on healthcare associated infections (HCAI); MRSA, MSSA and Gram-negative bacteraemia (Escherichia coli (E. coli), Pseudomonas aeruginosa ( P. aeruginoa), Klebsiella species (Klebsiella spp.)), and Clostridioides difficile (C. difficile) infection.

UKHSA (UK) · Jul 9, 2026

Accredited official statistics: Quarterly Epidemiological Commentary: mandatory MRSA, MSSA and Gram-negative bacteraemia and Clostridioides difficile infection, data up to July to September 2026

Epidemiological analyses of mandatory surveillance data on healthcare associated infections (HCAI); MRSA, MSSA and Gram-negative bacteraemia (Escherichia coli (E. coli), Pseudomonas aeruginosa ( P. aeruginoa), Klebsiella species (Klebsiella spp.)), and Clostridioides difficile (C. difficile) infection.

UKHSA (UK) · Jul 9, 2026

Accredited official statistics: Quarterly Epidemiological Commentary: mandatory MRSA, MSSA and Gram-negative bacteraemia and Clostridioides difficile infection, data up to April to June 2026

Epidemiological analyses of mandatory surveillance data on healthcare associated infections (HCAI); MRSA, MSSA and Gram-negative bacteraemia (Escherichia coli (E. coli), Pseudomonas aeruginosa ( P. aeruginoa), Klebsiella species (Klebsiella spp.)), and Clostridioides difficile (C. difficile) infection.

MHRA (UK) · Jul 9, 2026

Research: Use of UK plasma for the manufacture of five further plasma derived medicinal products and vCJD risk

The Medicines and Healthcare products Regulatory Agency (MHRA) published a review of the safety of albumins manufactured from UK-sourced plasma with respect to variant Creutzfeldt-Jakob disease (vCJD) risk in August 2023. A further review of the safety of five additional plasma derived medicinal products (Fibrinogen, Prothrombin Complex Concentrates (PCCs), C1 Esterase Inhibitor, Factor X and Protein C) manufactured from UK-sourced plasma with respect to vCJD risk has now been completed, with the results published in July 2026.

← NewerOlder →

Back to the live front page